Hailed as breakthrough treatments at their 2013 debut, the number of direct-acting antiviral (DAA) prescriptions to treat ...

Gilead HPI licensing adds $35M now + $330M milestones; Phase 2 starts by 2026; strong cash runway. Click for this ASMB update ...

Credit: Getty Images A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use. A 45-year-old White construction worker ...

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has ...

Background: Hepatitis C virus treatment is increasingly being offered in primary care because medications now require less frequent monitoring and have fewer adverse effects. However, many primary ...

LONDON, Jan 7 (Reuters) - GSK (GSK.L), opens new tab will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory applications, it said on ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe ...

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

Hepatitis C is a tiny virus with a significant impact. It's a small RNA virus that spreads through the blood and infects the liver. Even though today's medicines can cure it, hepatitis C remains a ...

Vir Biotechnology plans to give an exclusive license for the commercial rights to a chronic hepatitis delta treatment to an affiliate of Norgine. The biopharmaceutical company said Tuesday the license ...

The disease has become a key issue in Washington. We asked doctors to explain the ABCs. By Simar Bajaj On Friday, the Centers for Disease Control and Prevention’s vaccine advisory panel recommended ...

A group of independent vaccine advisers to the US Centers for Disease Control and Prevention is meeting this week, and a key item on the agenda is the hepatitis B vaccine. After presentations about ...